Amanda M Brock, J Clin Trials 2017, 7:5 (Suppl) DOI: 10.4172/2167-0870-C1-019

conferenceseries.com

4th International Conference on

Clinical Trials September 11-13, 2017 San Antonio, USA

The role of palliative care on phase 1 oncology clinical trial participants

Amanda M Brock

University of Pennsylvania, USA

Tntegration of Palliative Care into oncology care has been a challenge since the inception of palliative care programs. Phase 1 Loncology clinical trial participants are considered a distinctly vulnerable population. They are at high risk for lack of follow through by the healthcare system after being withdrawn from the clinical trial. In addition, they are at risk for therapeutic misconception and major challenges associated with dual enrollment on the trial and hospice programs. Patients with dual enrollment in palliative care and phase 1 trials could live longer lives, remain on trials for longer, have higher rates of advance directive completion, and may be more likely to die comfortably at home. Palliative Care consultation upon phase 1 trial enrollment can could improve the quality of the research being conducted as well as improve Quality of Life for trial participants.

Biography

Amanda M Brock has completed her Master of Bioethics and Master of Science in Nursing at the University of Pennsylvania. She has ten years' experience in direct patient care including inpatient and outpatient, nursing administration, and clinical research. She is experienced in leading committee work and creating nursing policies. She is a firm believer in systems thinking and the importance of clear and thoughtful communication in clinical care

manda.brock@gmail.com

Notes: